Literature DB >> 19531496

Characterization of phospholipase C gamma enzymes with gain-of-function mutations.

Katy L Everett1, Tom D Bunney, Youngdae Yoon, Fernando Rodrigues-Lima, Richard Harris, Paul C Driscoll, Koichiro Abe, Helmut Fuchs, Martin Hrabé de Angelis, Philipp Yu, Wohnwa Cho, Matilda Katan.   

Abstract

Phospholipase C gamma isozymes (PLC gamma 1 and PLC gamma 2) have a crucial role in the regulation of a variety of cellular functions. Both enzymes have also been implicated in signaling events underlying aberrant cellular responses. Using N-ethyl-N-nitrosourea (ENU) mutagenesis, we have recently identified single point mutations in murine PLC gamma 2 that lead to spontaneous inflammation and autoimmunity. Here we describe further, mechanistic characterization of two gain-of-function mutations, D993G and Y495C, designated as ALI5 and ALI14. The residue Asp-993, mutated in ALI5, is a conserved residue in the catalytic domain of PLC enzymes. Analysis of PLC gamma 1 and PLC gamma 2 with point mutations of this residue showed that removal of the negative charge enhanced PLC activity in response to EGF stimulation or activation by Rac. Measurements of PLC activity in vitro and analysis of membrane binding have suggested that ALI5-type mutations facilitate membrane interactions without compromising substrate binding and hydrolysis. The residue mutated in ALI14 (Tyr-495) is within the spPH domain. Replacement of this residue had no effect on folding of the domain and enhanced Rac activation of PLC gamma 2 without increasing Rac binding. Importantly, the activation of the ALI14-PLC gamma 2 and corresponding PLC gamma 1 variants was enhanced in response to EGF stimulation and bypassed the requirement for phosphorylation of critical tyrosine residues. ALI5- and ALI14-type mutations affected basal activity only slightly; however, their combination resulted in a constitutively active PLC. Based on these data, we suggest that each mutation could compromise auto-inhibition in the inactive PLC, facilitating the activation process; in addition, ALI5-type mutations could enhance membrane interaction in the activated state.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531496      PMCID: PMC2755714          DOI: 10.1074/jbc.M109.019265

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR.

Authors:  R A Laskowski; J A Rullmannn; M W MacArthur; R Kaptein; J M Thornton
Journal:  J Biomol NMR       Date:  1996-12       Impact factor: 2.835

2.  Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas.

Authors:  C L Arteaga; M D Johnson; G Todderud; R J Coffey; G Carpenter; D L Page
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Nuclear magnetic resonance structure of an SH2 domain of phospholipase C-gamma 1 complexed with a high affinity binding peptide.

Authors:  S M Pascal; A U Singer; G Gish; T Yamazaki; S E Shoelson; T Pawson; L E Kay; J D Forman-Kay
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

4.  Solution structure of the SH3 domain of phospholipase C-gamma.

Authors:  D Kohda; H Hatanaka; M Odaka; V Mandiyan; A Ullrich; J Schlessinger; F Inagaki
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

5.  Expression of phospholipases gamma 1, beta 1, and delta 1 in primary human colon carcinomas and colon carcinoma cell lines.

Authors:  K Nomoto; N Tomita; M Miyake; D B Xhu; P R LoGerfo; I B Weinstein
Journal:  Mol Carcinog       Date:  1995-03       Impact factor: 4.784

6.  Structural insights into formation of an active signaling complex between Rac and phospholipase C gamma 2.

Authors:  Tom D Bunney; Olaniyi Opaleye; S Mark Roe; Petra Vatter; Rhona W Baxendale; Claudia Walliser; Katy L Everett; Michelle B Josephs; Carolin Christow; Fernando Rodrigues-Lima; Peter Gierschik; Laurence H Pearl; Matilda Katan
Journal:  Mol Cell       Date:  2009-04-24       Impact factor: 17.970

7.  Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development.

Authors:  Q S Ji; G E Winnier; K D Niswender; D Horstman; R Wisdom; M A Magnuson; G Carpenter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1. Tyrosine 783 phosphorylation is not sufficient for lipase activation.

Authors:  Fujio Sekiya; Benoit Poulin; Yeun Ju Kim; Sue Goo Rhee
Journal:  J Biol Chem       Date:  2004-05-25       Impact factor: 5.157

9.  Catalytic domain of phosphoinositide-specific phospholipase C (PLC). Mutational analysis of residues within the active site and hydrophobic ridge of plcdelta1.

Authors:  M V Ellis; S R James; O Perisic; C P Downes; R L Williams; M Katan
Journal:  J Biol Chem       Date:  1998-05-08       Impact factor: 5.157

10.  Crystal structure of a mammalian phosphoinositide-specific phospholipase C delta.

Authors:  L O Essen; O Perisic; R Cheung; M Katan; R L Williams
Journal:  Nature       Date:  1996-04-18       Impact factor: 49.962

View more
  34 in total

1.  Role of amplification in phospholipase Cγ2 activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori: effect of ghrelin.

Authors:  B L Slomiany; A Slomiany
Journal:  Inflammopharmacology       Date:  2014-11-02       Impact factor: 4.473

Review 2.  Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind.

Authors:  Bertrand Boisson; Pierre Quartier; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2015-01-31       Impact factor: 7.486

3.  A protease-independent function for SPPL3 in NFAT activation.

Authors:  Stefanie L Makowski; Zhaoquan Wang; Joel L Pomerantz
Journal:  Mol Cell Biol       Date:  2014-11-10       Impact factor: 4.272

4.  Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ.

Authors:  Zhifeng Huang; William M Marsiglia; Upal Basu Roy; Nader Rahimi; Dariush Ilghari; Huiyan Wang; Huaibin Chen; Weiming Gai; Steven Blais; Thomas A Neubert; Alka Mansukhani; Nathaniel J Traaseth; Xiaokun Li; Moosa Mohammadi
Journal:  Mol Cell       Date:  2015-12-10       Impact factor: 17.970

5.  Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.

Authors:  Michael J Ombrello; Elaine F Remmers; Guangping Sun; Alexandra F Freeman; Shrimati Datta; Parizad Torabi-Parizi; Naeha Subramanian; Tom D Bunney; Rhona W Baxendale; Marta S Martins; Neil Romberg; Hirsh Komarow; Ivona Aksentijevich; Hun Sik Kim; Jason Ho; Glenn Cruse; Mi-Yeon Jung; Alasdair M Gilfillan; Dean D Metcalfe; Celeste Nelson; Michelle O'Brien; Laura Wisch; Kelly Stone; Daniel C Douek; Chhavi Gandhi; Alan A Wanderer; Hane Lee; Stanley F Nelson; Kevin V Shianna; Elizabeth T Cirulli; David B Goldstein; Eric O Long; Susan Moir; Eric Meffre; Steven M Holland; Daniel L Kastner; Matilda Katan; Hal M Hoffman; Joshua D Milner
Journal:  N Engl J Med       Date:  2012-01-11       Impact factor: 91.245

6.  Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis.

Authors:  Peng Zhang; Yiqing Zhao; Xiaofeng Zhu; David Sedwick; Xiaodong Zhang; Zhenghe Wang
Journal:  Mol Cancer Res       Date:  2011-08-12       Impact factor: 5.852

7.  Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes.

Authors:  Nicole Hajicek; Thomas H Charpentier; Jeremy R Rush; T Kendall Harden; John Sondek
Journal:  Biochemistry       Date:  2013-07-09       Impact factor: 3.162

8.  A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.

Authors:  Qing Zhou; Geun-Shik Lee; Jillian Brady; Shrimati Datta; Matilda Katan; Afzal Sheikh; Marta S Martins; Tom D Bunney; Brian H Santich; Susan Moir; Douglas B Kuhns; Debra A Long Priel; Amanda Ombrello; Deborah Stone; Michael J Ombrello; Javed Khan; Joshua D Milner; Daniel L Kastner; Ivona Aksentijevich
Journal:  Am J Hum Genet       Date:  2012-09-20       Impact factor: 11.025

9.  The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.

Authors:  Claudia Walliser; Elisabeth Hermkes; Anja Schade; Sebastian Wiese; Julia Deinzer; Marc Zapatka; Laurent Désiré; Daniel Mertens; Stephan Stilgenbauer; Peter Gierschik
Journal:  J Biol Chem       Date:  2016-08-19       Impact factor: 5.157

Review 10.  Phosphoinositides: tiny lipids with giant impact on cell regulation.

Authors:  Tamas Balla
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.